NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » TOP 50 Pharmas » Pfizer  1  2  » 
found files: 24
Pfizer »24/05/2007 [Industry news]
Pfizer Says Research and Development Head John LaMattina Will Retire This Year

Pfizer said today that the President of Pfizer Global Research and Development, Dr. John LaMattina, who made many important contributions to the Company‚Äôs research division throughout his 30-year career, will retire from Pfizer by the end of this year. The company will begin a search both inside and outside the company for his successor, and Dr. LaMattina has agreed to remain during this period to ensure a smooth transition....   more»

Pfizer »09/12/2007 [Company watch]
Pfizer looks to expand R&D presence in Asia

Pfizer Inc, the world's biggest drug maker, wants to expand its research and development activities in Asia, targeting China, India, Japan, and South Korea, an executive said on Friday. Pfizer, who makes blockbuster anti-cholesterol drug Lipitor and the erectile dysfunction drug Viagra, opened a research centre in Shanghai in 2005 and aims to expand clinical research activities globally, with nearly 80 studies ongoing....   more»

Pfizer »08/03/2008 [Company watch]
Pfizer plans to cut costs and expand in China

Pfizer says it is planning to outsource more drug manufacture, to lower costs ahead of the generic competition for its cholesterol drug Lipitor, and to continue expansion broadly in China. Lipitor's patent expires at the end of 2011. At the same time Pfizer reaffirmed its profit forecast for 2008 with anticipated revenue of $48.08 Billions....   more»

Pfizer »09/06/2008 [Company watch]
Pfizer to acquire Tianjin Tianyao Pharmaceutical

Chinese media reports that pharmaceutical giant Pfizer is negotiating with Tianjin Tianyao Pharmaceutical (SHA: 600488) for possible acquisition of the company. Tianjin Tianyao Pharmaceuticals is China's biggest manufacturer of Glucocorticoid APIs and second only to Pfizer in world production. Tianyao generated revenues of RMB 698.9 million in 2007, and reported net income of RMB 26 million, a decrease of 42% compared with the same period in 2006. The company is regarded as an industry leader in China. The Tianjin municipal government, which is trying to build a pharmaceutical park, has welcomed Pfizer into the city....   more»

Pfizer »13/06/2008
Novamed selected as Pfizer/Baxter China Strategic Partner

NovaMed Pharmaceuticals Inc, a leading China-based pharmaceutical company which provides outsourced drug development and commercialization services for global multinational pharmaceutical and biotechnology companies and Pfizer China today announced an exclusive strategic partnership in the oncology area. The agreement indicates that NovaMed will serve as Pfizer China‚Äôs sole distributional and promotional partner for six of its oncology products throughout mainland China starting June, 2008. It is the first alliance of its kind for Pfizer China‚Äôs oncology portfolio. The partnership creates a window of opportunity in China‚Äôs health care environment in which multinationals can strategically outsource established drugs to companies with wide and well-established distribution networks across the country. With cancer ranked the leading cause of mortality in China, an annual increase of 1.6-1.7 million cancer patients is expected in addition to the approximately 4.5 million existing oncology patients. The unique outsourcing model significantly increases the number of patients benefiting from clinically proven and effective therapies. NovaMed expects a 30-40% increase in hospital coverage of these six Pfizer China oncology drugs across China. NovaMed has continued to strengthen its position in China‚Äôs oncology market since its first oncology deal with Baxter China for three of its long-standing oncology products. With a total market value of RMB 40 billion, the oncology therapeutic area is the second largest in China, after the antibiotic market. Its current oncology portfolio offers a wide range of therapies across key disease areas including medical oncology, hematology and urology. NovaMed will also continue to pursue the licensing of oncology products from international companies‚Äď these include both products that have been launched in international markets (but are not yet available in China) and products which are currently still in the development cycle. Mark Lotter, CEO and co-founder of NovaMed, commented, ‚ÄúNovaMed is committed to partnering with global pharmaceutical companies to help international drug brands achieve their full potential in an emerging market such as China and to allow a wider population of patients in China to gain access to best-in-class drugs. NovaMed has established a solid foundation for building an oncology portfolio which positions the company well in terms of its immediate, medium and long term presence in the oncology market in China.‚ÄĚ Oncology is a rapidly growing therapeutic area internationally with the sales of cancer drugs expected to double at the rate of the global pharmaceutical market and reach USD 80 billion by 2012 according to a recent IMS report. ‚ÄúPfizer China is delighted to have the opportunity to partner with NovaMed. NovaMed‚Äôs oncology team excels in terms of its abundant distribution and marketing experience and expertise, as well as its solid relationships with key oncology centers and thought leaders across the nation. All of these factors will greatly aid the promotion of oncology products, help bring more treatment options to the market and ultimately benefit a larger proportion of oncology patients,‚ÄĚ said Xiaoyu Sun, Associate Director of the Commercial and Retail Business Department at Pfizer China. According to Thomas Zan, Director of Critical Care Business Unit at Baxter China, ‚ÄúNovaMed‚Äôs in-depth knowledge and understanding of China‚Äôs oncology environment is the key to its success. We have been very impressed with NovaMed‚Äôs strong and dedicated management team and the uniquely sustainable business model it offers to China‚Äôs oncology market. Since signing the deal for three of our oncology products in September 2007, NovaMed has demonstrated its solid execution capability through building extensive alliances with oncology distributors and partners across the country and facilitating hospital listing, tendering and pricing.‚ÄĚ NovaMed‚Äôs exclusive distributional and promotional agreement with Pfizer China allows access to six of Pfizer's oncology products within China: Adriamycin, Daunoblastina, Leucovorin, Methotrexate, Estracyt and Farlutal. The three oncology products from Baxter China are Holoxan, Mesna and Endoxan. These key partnerships have effectively catapulted NovaMed into becoming a highly competitive force in China‚Äôs oncology market. Together with its leading commercial team, it continues to be an attractive target as a partner for global companies who wish to maximize their presence in China....   more»

Pfizer »24/06/2008 [Company watch]
NovaMed to distribute six oncology products for Pfizer China

NovaMed Pharmaceuticals announced June 13 that is has entered into an agreement with Pfizer China under which it will act as the exclusive distributor and promoter for six of Pfizer China's anticancer products. NovaMed expects hospital coverage of the products, Adriamycin, Daunoblastina, Leucovorin, Methotrexate, Estracyt and Farlutal, to increase by 30% to 40% in China. NovaMed is a specialty pharmaceutical company providing commercialization and outsourcing services in China for global pharmaceutical and biotech companies. The company seeks to license products that have been launched in international markets but are not yet available in China as well as development stage products. NovaMed has successfully in-licensed programs from several multinational pharmaceutical companies, including recent agreements with Sanofi-Aventis, Baxter International, and Meda AB....   more»

Pfizer »01/07/2008 [Company watch]
Pfizer Cuts Costs by Outsourcing Drug Distribution in China

NovaMed will sell and promote six anti-tumor drugs in China for Pfizer China, a subsidiary of big pharma company Pfizer Inc. (NYSE: PFE). The contract began in June 2008. Pfizer China projects that the out-sourcing will increase its coverage ratio in China hospitals for the products by 30% to 40%. NovaMed will be responsible for distribution and promotion of Pfizer China's adriamycin, dauniblastina, leucoyorin, methotrexate, estracyt, and farkutal. The marketing out-sourcing contract is a first for Pfizer China. Worldwide, its Pfizer parent company is determined to cut costs by increasing its use of out-sourcing, though this was expected to occur mainly in the manufacturing sector. Pfizer will close or sell 45 pharmaceutical factories, and to increase its total outsourcing from 10% currently to 30% in two years....   more»

Pfizer »09/09/2008 [Company watch]
Pfizer and Medivation Enter into Global Agreement to Co-Develop and Market Dimebon for the Treatment of Alzheimer\'s and Huntington\'s Diseases

Pfizer Inc and Medivation, Inc. announced today that they have entered into an agreement to develop and commercialize Dimebon, Medivation\'s investigational drug for treatment of Alzheimer\'s disease and Huntington\'s disease. Dimebon currently is being evaluated in an international, confirmatory Phase III trial in patients with mild-to-moderate Alzheimer\'s disease ( Under the terms of the agreement, Medivation will receive an up-front cash payment of $225 million. Medivation also is eligible to receive payments of up to $500 million upon the attainment of development and regulatory milestones plus additional undisclosed commercial milestone payments. Medivation and Pfizer will collaborate on the Phase III program in Alzheimer\'s disease, Huntington\'s disease development and regulatory filings in the United States. The companies will share all U.S. development and commercialization expenses along with U.S. profits/losses on a 60 percent/40 percent basis, with Pfizer assuming the larger share of both expenses and profit/losses. In addition, Medivation will co-promote Dimebon to specialty physicians in the U.S. Pfizer will have responsibility for development, regulatory and commercialization outside the U.S. and will pay Medivation tiered royalties on commercial sales outside of the U.S. The agreement is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. J.P. Morgan served as financial advisor, and Cooley Godward Kronish LLP served as legal advisor, to Medivation on this transaction. Alzheimer\'s disease leads to the death of brain cells and the loss of nerve connections in areas of the brain that govern memory, thinking and behavior. Alzheimer\'s disease gradually destroys a person\'s memory and ability to learn, reason, make judgments, communicate and carry-out daily activities. No currently marketed Alzheimer\'s disease drug appears to stop brain cell death and prevent or restore lost nerve connections. Dimebon is an orally-available, small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer\'s disease and Huntington\'s disease, making it a potential treatment for these and other neurodegenerative conditions. Based on preclinical data generated to date, Dimebon appears to improve the function of mitochondria, the energy generators in cells that play a vital role in governing brain cell health, growth and overall function. Dimebon also has been shown to stimulate the outgrowth of nerves from brain cells, or neurites, a process that is believed to play an important role in restoring or generating new brain cell connections. \"With more than 18 million people worldwide suffering from the debilitating and ultimately fatal effects of Alzheimer\'s disease, Pfizer has made this devastating illness one of our highest priorities,\" said Dr. Martin Mackay, president, Pfizer Global Research and Development. \"We are working to develop new medicines that improve memory and halt or significantly slow the disease\'s progression. We look forward to collaborating with Medivation to bring Dimebon to patients as rapidly as possible.\" \"After a rigorous process that garnered substantial interest, we believe that Pfizer is the ideal partner, sharing our vision for Dimebon and capable of maximizing its potential globally,\" said Dr. David Hung, president and chief executive officer of Medivation. \"As one of the leaders in Alzheimer\'s disease, Pfizer is an optimal partner because of its extensive experience developing new medicines; its marketing and commercialization track record; and, its significant global capability to effectively reach primary care physicians, who today prescribe the vast majority of Alzheimer\'s disease medications in the U.S.\" About Dimebon\'s Clinical Program Results from the first pivotal trial of Dimebon in Alzheimer\'s disease showed that patients treated with Dimebon experienced statistically significant improvements compared to placebo in key aspects of the disease -- memory and thinking, activities of daily living, behavior and overall function. Dimebon\'s benefit over placebo continued to increase throughout the 12-month treatment period. At the end of 12 months, Dimebon-treated patients were on average functioning as well or better than they had been at the start of the study on each of 5 clinical endpoints. These results were published in the July 19, 2008 issue of The Lancet, and are noteworthy as untreated Alzheimer\'s patients progressively deteriorate over time in these areas. On July 7, 2008, Medivation announced positive safety and efficacy results from its Phase 2 trial of Dimebon in Huntington\'s disease, which was conducted in collaboration with the Huntington Study Group. Dimebon appeared to be well tolerated and showed statistically significant benefit versus placebo in cognition as measured by the Mini-Mental State Examination, a secondary endpoint in the study....   more»

Pfizer »20/11/2008 [Company watch]
Stiff legal battle over Viagra continues, Pfizer wins latest round

Pfizer\'s drawn out battle with Guangzhou Welman Pharmaceutical continues, this time with the courts ruling in favor of the multinational drug giant in a counter suit filed by Welman....   more»

Pfizer »16/01/2009 [Company watch]
Drugmaker Pfizer cutting up to 2,400 sales jobs ahead of Lipitor generics

Drug giant Pfizer Inc. reportedly plans to lay off nearly a third of its 8,000 salespeople....   more»

Pfizer »21/03/2009 [Company watch]
Pfizer, PlaNet Finance Partner to Study Options for Expanding Access to Healthcare in China

The Chinese Ministry of Health recently released the results of its 4th National Health Survey, an extensive document covering healthcare patterns across the country. The Pfizer and PlaNet Finance collaboration is designed to solicit additional information from low-income populations in China to complement existing and planned government efforts to improve healthcare....   more»

Pfizer »30/03/2009 [Company watch]
Pfizer Inc and PlaNet Finance announced today that they will team up to conduct an in-depth research project on the healthcare needs of the working poor in China.

The Chinese Ministry of Health recently released the results of its 4th National Health Survey, an extensive document covering healthcare patterns across the country....   more»

»22/06/2009 [Company watch]
Pfizer aims for No.1 spot

Pfizer will use acquisitions and partnerships in an effort to become the number one drug seller in emerging markets such as China....   more»

»30/07/2009 [Company watch]
Pfizer, Fudan University ally for clinical research training

Healthcare major Pfizer is partnering with Fudan University of China to establish a graduate program in Clinical Data Management and Statistical Programming. This three year Masters Degree program, a first of its kind in China, is designed to develop qualified professionals to support clinical research which is rapidly increasing in China....   more»

Pfizer »08/08/2009 [Company watch]
Pfizer grows R&D work in China

In its bid to dominate the global marketplace, drug maker Pfizer Inc has to bet on more than just a mega-merger with Wyeth. Indeed, the worlds largest pharmaceutical company is also busy expanding its presence in China to capitalize on the countrys growing role in the worlds pharmaceutical market....   more»

Pfizer »19/08/2009 [Industry news]
Pfizer bids to recapture Viagra China brand name falls limp

The Supreme Peoples Court of China has rejected Pfizers appeal to turn over a previous ruling regarding Pfizer s brand name rights to its erectile dysfunction (ED) drug Viagra,...   more»

»10/11/2009 [Company watch]
Pfizer Cutbacks Reflect Difficulties Facing Big Pharma

Pfizer announced it would close six out of its 20 R&D facilities around the globe...   more»

Pfizer »11/11/2009 [Industry news]
BMP Sunstone Partners with Pfizer to Distribute Endometriosis Treatment in China

BMP Sunstone Corporation and Pfizer China (NYSE: PFE) have formed a strategic partnership to distribute and promote Depo-Provera (Medroxy-progesterone Acetate), a Pfizer product used to treat endometriosis, in China....   more»

Pfizer »20/11/2009 [Company watch]
Pfizer Is Best Positioned Big Pharma in China

In an investment review of Pfizer, Goldman Sachs said sales in emerging growth markets would become a significant factor in the company‚Äôs revenues, a fact that it considers underappreciated by stock market investors. China is the major emerging market for Pfizer....   more»

»26/11/2009 [Company watch]
Pfizer Increases R&D Commitment in China

Pfizer (NYSE: PFE) will expand its China R&D operations by adding facilities in central and western China, according to a Reuters story. The company will build a new clinical R&D center in Wuhan, which will support global clinical drug programs, including Phase I-IV clinical trials. Pfizer did not announce the size of capital commitment to the new R&D center....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.